Podcasts about zepbound

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45]; Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45]; How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15]; Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30]; Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15]; The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00]; Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45]; Why lean mass measurements are an imperfect proxy for muscle health and function [21:45]; The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00]; Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00]; Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00]; Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45]; Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00]; Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00]; Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45]; Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15]; Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00]; The risks of using gray-market retatrutide before FDA approval [52:15]; Key takeaways [54:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode of On The Pen, Dave Knapp sits down with obesity medicine expert Angela Fitch to break down exactly who qualifies, how to apply, which medications are covered, and what this historic expansion of obesity treatment access means for patients across America.We discuss:✅ Medicare Bridge Program eligibility requirements✅ Zepbound, Wegovy, Foundayo (orforglipron), and GLP-1 coverage updates✅ BMI and comorbidity qualifications✅ Prediabetes, sleep apnea, cardiovascular disease, and obesity treatment access✅ How Medicare patients can obtain GLP-1 medications✅ Why obesity is finally being treated as a chronic disease✅ The future of obesity medicine and Medicare coverage✅ Concerns about access to care vs access to medication✅ Muscle loss, nutrition, strength training, and healthy weight loss✅ The Treat and Reduce Obesity Act (TROA)This may be one of the most important developments in obesity treatment history, potentially opening the door for millions of Americans living with obesity, prediabetes, cardiovascular disease, and other weight-related conditions to receive evidence-based care.

Why aren't there more medical insurance plans that cover alternative medicine? Solutions for Long Covid; MK7 vitamin K slows arterial calcification; Keto diet shows promise for treatment of anorexia; It's not so much salt restriction—it's the dietary sodium/potassium ratio in hypertension; Study finds multivitamins don't keep you from getting Covid—but when you get it, it's milder; Incidence of social anxiety disorder is soaring among young people.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)What if Medicare finally made GLP-1 medications for weight management more affordable — could this be the moment that changes access for millions of people?Today, we're talking about something that's been years in the making in the world of obesity care: the expanded coverage of anti-obesity medications for patients on Medicare. Starting July 1st, eligible Medicare beneficiaries have a real opportunity to access GLP-1 receptor agonist medications at a much more affordable monthly cost through a new federal program — and for many patients, this could mark a major shift in access to treatment that's historically been limited or completely out of reach under Medicare's coverage rules.This change didn't happen overnight. It comes after years of advocacy, policy discussions, and ongoing efforts to get obesity recognized as a chronic medical condition that deserves treatment just like any other disease. In this episode, we break down where this program came from, how it connects to the bigger picture of obesity care, who it applies to, and everything you need to know about eligibility, covered medications, and how the process actually plays out in real life.Topics discussed:How the Bridge Program Could Expand Access to Obesity MedicationsFor the First Time, Medicare Is Opening the Door to Obesity MedicationsThe BMI and Health Condition CriteriaWhy the Reason for Your Prescription Matters Just as MuchThe Details That Make a Real Difference — Prior BMI and Lifestyle SupportThe List of Weight Loss Medications Covered by the Bridge ProgramWant the full breakdown? This episode covers all the details on eligibility, covered medications, and what this program could mean for you or someone you love navigating Medicare and obesity treatment. Find it wherever you get your podcasts — and if it helps, share it with someone who might need to hear it too.Resources mentioned in this episode:GLP-1 Prescribers Guide — CMSMedicare GLP-1 Bridge Program Details — CMSConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

What happens when GLP-1 medications stop working the way you hoped they would? In this mailbag episode, Dr. Emily Cooper answers listener questions about fasting, insulin levels, PCOS, lipedema, plateaus on Zepbound, and the complicated reality behind metabolic dysfunction. From the dangers of under-fueling to why individualized treatment matters so much, this conversation unpacks the science behind weight resistance with clarity and compassion.Key TakeawaysWhy fasting and restrictive eating may worsen metabolic adaptationThe real role insulin plays in metabolic healthHow PCOS and lipedema complicate weight loss treatmentWhy some people plateau on GLP-1 medications over timeThe importance of fueling, muscle preservation, and individualized careLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

What is GLP-1 microdosing, and can smaller doses of medications like Ozempic, Wegovy, and Zepbound lead to better long-term weight loss results?In this episode, registered dietitian Zoe is joined by Deidre, FNP, to break down one of the biggest conversations in obesity medicine right now: GLP-1 microdosing. They explain how microdosing differs from standard manufacturer dosing, why FDA-approved dosing schedules are designed for clinical trials, and why a one-size-fits-all approach may not work for every patient.Deidre explains how slower, smaller dose increases may help reduce side effects like nausea and abdominal discomfort, while still supporting hunger control, fewer cravings, less food noise, and gradual weight loss. They also discuss super responders, non-responders, compounded medications, and why personalized GLP-1 dosing can make a major difference in long-term maintenance.They also unpack the debate around GLP-1 microdose marketing, including the recent dispute involving Eli Lilly, Noom, and tirzepatide, and what it means for patients navigating telehealth weight loss programs.Most importantly, Zoe and Deidre explain why medications are only one part of obesity treatment. Sustainable weight loss still depends on nutrition, whole foods, protein, fiber, lifestyle changes, and long-term support.

A few years ago, I came across a quote that said:"I think the key to a happy life as an adult woman is to channel your inner weird little girl and make her happy."It immediately resonated with me.I was the kid making potions in the yard, obsessed with magic books, fortune tellers, mood rings, crystals, and all things mystical. And the older I get, the more I realize those parts of me never disappeared—they just got buried under adulthood and responsibility.In this episode, I'm talking about whimsy—not as a trend, but as a way of reconnecting with yourself. I'm sharing what's on my whimsical summer list, why I've been intentionally making more room for wonder, and how this connects to one of the core principles of Irresistible You: Feed Your Soul.Because maybe creating a magical life isn't about becoming someone new.Maybe it's about remembering who you've been all along. ✨

ABC's Jim Ryan joins Arizona’s Morning News to talk about the new black market for next-gen diet drugs like Wegovy and Zepbound. People are so eager to try them that they’ll jump the gun on FDA approvals. 

This episode explores how to use GLP-1 medications like semaglutide/Ozempic and tirzepatide/Mounjaro safely and effectively. Dr. Mike Hart and Dr. Christle Guevarra Do discuss once-weekly dosing, individualized titration, optimal dose selection, food noise, appetite suppression, and the risks of dosing mistakes with vials or gray-market peptides. They also cover why resistance training, protein, fiber, and realistic nutrition habits are essential for preserving muscle and maintaining results. The conversation expands into GLP-1 benefits beyond weight loss, including cardiovascular protection, inflammation, autoimmune flares, addiction-related behaviors, alcohol cravings, libido, menstrual cycles, PCOS, sleep apnea, and what to expect when stopping the medication. Dr. Christle Guevarra Do is a physician focused on obesity medicine, GLP-1 education, weight management, and sustainable lifestyle change. Drawing from both her clinical experience and her own long-term use of GLP-1 medication, she helps patients understand how these medications fit into the bigger picture of long-term health. Her approach emphasizes individualized care, strength training, nutrition, behavior change, and realistic maintenance strategies rather than quick fixes. In this episode, she shares practical guidance for using GLP-1s responsibly while protecting muscle, managing hunger, and building habits that support lasting results. Dr. Christle Guevarra Website https://www.drchristle.com/ Dr. Christle's Free GLP-1 Guide https://www.drchristle.com/glp1-guide Dr. Christle Instagram https://www.instagram.com/dr.christle/ Ozempic — semaglutide https://www.ozempic.com/ Wegovy — semaglutide for weight management https://www.wegovy.com/ Mounjaro — tirzepatide https://mounjaro.lilly.com/ Zepbound — tirzepatide for weight management / sleep apnea https://zepbound.lilly.com/ FDA: Concerns With Unapproved GLP-1 Drugs https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Retatrutide Clinical Trial Info https://clinicaltrials.gov/study/NCT05882045 Vyvanse — lisdexamfetamine https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad Creatine — NIH Supplement Info https://ods.od.nih.gov/factsheets/ExerciseAndAthleticPerformance-HealthProfessional/ Psyllium Husk / Fiber — MedlinePlus https://medlineplus.gov/druginfo/meds/a601104.html Berberine — NCCIH https://www.nccih.nih.gov/health/berberine-and-weight-loss-what-you-need-to-know Tesamorelin — MedlinePlus https://medlineplus.gov/druginfo/meds/a611035.html CJC-1295 — PubMed Research https://pubmed.ncbi.nlm.nih.gov/16352683/ Ipamorelin — PubMed Research https://pubmed.ncbi.nlm.nih.gov/9849822/ FDA: Peptides / Compounding Safety Concerns https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks Oura Ring https://ouraring.com/ White Claw https://www.whiteclaw.com/   Show Notes 00:00 Welcome to the Hart2Heart Podcast 00:45 Weekly Dosing Debate 03:41 Starting Dose Basics 06:28 Pens vs Vials Safety 08:37 Finding Your Sweet Spot 11:01 Nighttime Binge Window 13:32 Lifestyle Work Still Matters 14:30 Benefits Beyond Weight 17:27 Libido and Low Calories 22:26 Alcohol Hits Different 24:59 Cancer Claims Reality Check 26:59 Strength Training Priority 29:06 Supplements and Creatine 29:38 Creatine Protein Fiber Basics 31:50 Berberine Pros and Cons 32:37 Peptides Sleep and Muscle 35:28 Too Lean for GLP-1 38:52 Cycles PCOS and Fertility 40:45 Food Noise vs Appetite 44:42 Staying On or Stopping 49:19 Heart Rate and HRV Concerns 51:38 Ozempic vs Mounjaro Choices 54:45 Sleep Apnea and Wrap Up The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

What Really Happens Inside an Obesity Clinic GLP-1 medications are everywhere right now. Patients are asking about Ozempic, Wegovy, Zepbound, compounded medications, muscle loss, “Ozempic face,” insurance denials, and what happens when the weight loss slows down.But what does obesity medicine actually look like inside the clinic? In this episode, I'm joined by Joseph Zucchi, PA-C, clinical supervisor and physician associate at Transition Medical Weight Loss in Salem, New Hampshire. This is not your typical GLP-1 conversation. We're going beyond protein goals, nausea tips, and constipation management to talk about what clinicians are really facing in practice: how to dose these medications, when to switch, and how to support patients when insurance coverage disappears.In this episode, you'll learn:What to assess when a patient hits a weight loss plateau beyond simply increasing the dose  How to talk with patients about GLP-1 concerns like muscle loss, thyroid cancer warnings, GI side effects, and “Ozempic face”  Why obesity medications are tools, not “cheating,” and how to address weight stigma in the exam room  What clinicians should know about compounded GLP-1 medications and why FDA-approval matters  How to document for prior authorizations and what insurance companies are often looking for  What happens when patients lose GLP-1 coverage and how to discuss alternative medication options  What Joe is most excited about in the future of obesity medicine, including new medications and expanding coverage If you prescribe GLP-1 medications, counsel patients on weight management, or feel overwhelmed by the insurance and documentation side of obesity medicine, this episode will give you a practical, behind-the-scenes look at what comprehensive obesity care can look like.Connect with JoeResources mentioned:Obesity Medicine Nutrition Course (with a 2026 medication update) Use code POD15 for 15% off!155 | Unstuck: Strategies for Sustainable Weight Loss151 | Are GLP-1s Masking Undiagnosed Eating Disorders?Obesity Medication InfographicAny Questions? Send Me a MessageSupport the showConnect with Colleen:InstagramLinkedInSign up for my FREE Newsletter - Nutrition hot-topics delivered to your inbox each week.Disclaimer: This podcast is a collection of ideas, strategies, and opinions of the author(s). Its goal is to provide useful information on each of the topics shared within. It is not intended to provide medical, health, or professional consultation or to diagnosis-specific weight or feeding challenges. The author(s) advises the reader to always consult with appropriate health, medical, and professional consultants for support for individual children and family situations. The author(s) do not take responsibility for the personal or other risks, loss, or liability incurred as a direct or indirect consequence of the application or use of information provided. All opinions stated in this podcast are my own and do not reflect the opinions of my employer. 

This week it's just Steven and Devon holding down the fort while Ben is away, which means the conversation somehow manages to jump from guitar maintenance to Star Wars collectibles to post-apocalyptic murder mysteries without missing a beat. Real Life Devon spent part of the week giving some attention to an old Kelly-style guitar that had been fighting him for years. After wrestling with the floating tremolo system, he explains the joys and frustrations of guitar intonation and why getting everything properly adjusted can feel more like engineering than music. With the guitar finally behaving itself, he's been spending time learning Vivaldi's Summer, proving once again that classical music can be every bit as metal as heavy metal. Meanwhile, Steven returned from a Disney trip with a collection of souvenirs that may or may not require their own dedicated shelf. The haul includes a Spira gift card, a BB-series droid, a C-series droid head popcorn bucket, a Grand Holocron, a new Star Wars font hat, and nearly every Kyber crystal available. Unfortunately, despite collecting the entire rainbow, none of the elusive secret crystals made their way home. Such is the way of the Force. Future or Now Devon dives into Paradise on Hulu, starring Sterling K. Brown. What initially appears to be a political thriller quickly reveals itself to be something much stranger. Without spoiling too much, the series combines a whodunit mystery with a post-apocalyptic setting and some surprisingly deep character development. The show's vision of "The American Dream Underground" becomes one of the most fascinating aspects of the story, and Devon argues that the character work is what truly elevates the series above similar mystery shows. The conversation also briefly touches on Hoppers, now available on Disney+. The verdict? It's definitely strange. Whether that strangeness is good or bad may depend entirely on your tolerance for Pixar-style weirdness. There may also be connections to the Pixar Theory, but there simply isn't enough time to open that particular can of worms. Steven brings an interesting study examining the real-world effects of popular GLP-1 weight-loss medications like Ozempic, Wegovy, Mounjaro, and Zepbound. Researchers analyzing Fitbit data discovered that while patients successfully lost weight after starting the medications, many also became less physically active. Daily step counts and exercise levels declined, raising concerns because these drugs can reduce muscle mass alongside fat loss. The findings highlight an important reminder: losing weight and maintaining physical fitness aren't necessarily the same thing, and preserving strength remains a critical part of long-term health. Links Paradise (IMDb): https://www.imdb.com/title/tt27444205 Weight-loss medication activity study: https://www.sciencedaily.com/releases/2026/06/260614011841.htm   This episode covers everything from guitar maintenance and Disney loot to dystopian mysteries and the surprising relationship between weight loss and physical activity. Just another normal week on Science Faction.

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down witH ​⁠ to break down the molecules, clinical trials, weight loss results, and safety signals that could define the next generation of obesity and diabetes medicine.We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more!From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases?In this episode:✅ Survodutide obesity and liver fat reduction data✅ Mazdutide Phase 3 obesity and diabetes results✅ UBT251 triple agonist weight loss data✅ Berobenatide (MET-097) long-acting GLP-1 updates✅ CagriSema diabetes and obesity trial results✅ Zenagamtide (Amycretin) injectable and oral development✅ Petrelintide amylin agonist info✅ Future GLP-1, GIP, glucagon, and amylin therapiesThe future of obesity medicine is no longer just about who produces the most weight loss. It's about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale.Read more obesity medicine news at obesity.news

Worried about gaining weight back after Ozempic, Wegovy, Mounjaro, or Zepbound?You're not alone. One of the biggest concerns people have during their GLP-1 journey is what happens after the weight loss phase—and how to actually maintain their results long-term.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down what sustainable weight maintenance really looks like, why maintaining weight loss is different from losing weight, and the habits that support long-term success.Because keeping weight off isn't about being perfect. It's about building routines that you can realistically maintain for years to come.We're covering:Why weight maintenance is different than weight lossCommon reasons people regain weight after losing itThe role of appetite, food noise, and long-term behavior changeWhy protein and strength training matter for maintenanceHow muscle supports long-term health and weight managementThe mindset shifts that make maintenance easierWhy all-or-nothing thinking keeps people stuckWhat successful long-term maintenance actually looks likeWhether you're currently taking Ozempic, Wegovy, Mounjaro, or Zepbound—or simply thinking ahead to the future—this episode will help you focus on the habits that support lasting results.

Can retatrutide finally be the breakthrough obesity treatment we've been waiting for? The answer is yes—and the data is stunning. In this episode I'm walking you through the biggest obesity medicine discovery from the ADA's 86th Scientific Session: retatrutide, a triple hormone receptor agonist showing weight loss results that rival bariatric surgery. You'll learn what makes retatrutide different from Wegovy and Zepbound, the stunning results from the Triumph 1 trial, what the side effects actually look like, and when this medication will finally be available. Weight loss medications are evolving faster than ever. But what you really need to know is what these results mean for your health. Listen now! Episode Highlights: Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors Participants lost an average of 28.3% of their body weight in 80 weeks Two-thirds of participants achieved a normal BMI—moved from obese to healthy weight Nearly everyone with prediabetes reversed it and returned to normal blood sugar Over 70% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity The highest discontinuation rate due to side effects was only 11%—mainly GI issues Retatrutide is not yet FDA approved but anticipated to launch early 2027 Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In Part 2 of this series, we're diving into the practical nutrition strategies that can help you feel your best while taking medications like Ozempic, Mounjaro, and Zepbound.From constipation and digestive changes to hitting your protein goals with a low appetite, this episode focuses on the habits that support long-term success and help you maintain your results. We'll cover:• Why constipation is so common on GLP-1 medications and how to prevent it• How to reach your protein goals when you get full quickly• What to do when protein foods don't sound appealing• How GLP-1 medications change hunger and fullness cues• What to expect if you need to temporarily stop your medicationGLP-1 medications can be powerful tools, but they work best when paired with the right nutrition and lifestyle habits. Learning how to fuel your body, support digestion, and adapt to your changing appetite is key to protecting your health while achieving sustainable weight loss.WORK WITH US:O​​ntario-Wide Virtual Obesity Management Clinichttps://www.highmetabolicclinic.comJoin my Weight Loss Coaching Program for women, Best Weight https://www.sashahighmd.com/bestweightRecover Strong for Binge Eatinghttps://www.sashahighmd.com/bedTaking the first step toward weight loss can feel overwhelming — but you don't have to do it alone. I've created a curated list of my podcast episodes to gently guide you as you begin your journey. https://www.sashahighmd.com/podcast-guide

It's been impossible to keep up with tennis news lately, with Serena's return, the grass season starting, and the top players continuing to pressure the Slams on prize money and consultation. We had too much on our Roland Garros wrap agenda, so here's the twin to episode 425. We talk about Serena's long-simmering “comeback,” the product tie-ins with Ro and Zepbound, and her successful doubles match with Canadian star Victoria Mboko. We also check in with the ongoing player response to prize money increases (as a proportion of tournament revenue) and what could come next. Finally, we give our unorganized thoughts on the Rafa doc, check in with a kind Reddit user, and give you a Knicks segment that is now -- thankfully -- a time capsule of life before Jalen Brunson was an MVP and NBA champion! 1:30 The "wildfire" … was warranted  11:30 Serena and Vicky ace their first (and only) test 23:10 Is this comeback meant to be a proof of concept for GLP-1 use? 33:10 Wimbledon prize money -- will the increase be enough for “Project Red Eye?” 40:00 Netflix's Rafa documentary was a somewhat harrowing experience 49:30 Admitting I was wrong is important! 52:40 A quick Knicks segment (now a time capsule)

In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40

The Layoff Tracker, Cigna's GLP-1 Cut & What Happens When Compliance FailsJune 8th, 2026. Bo and Luke break down three stories connected by the same thread: what happens when organizations wait too long to act.

GLP-1 medications like Ozempic, Wegovy, and Zepbound have become some of the most talked-about treatments for weight loss, but their benefits may extend far beyond the scale. In this episode, Diana breaks down what GLP-1 medications are, how they work in the body, and what current research shows about kidney health. She explores the growing evidence for kidney protection, discusses emerging research in autosomal dominant polycystic kidney disease (ADPKD), and shares practical considerations for people with PKD who are considering semaglutide or tirzepatide medications. SHOW NOTES, REFERENCES, & TRANSCRIPTS www.thepkddietitian.com/58 Episode #57: Weight Loss & PKD: Can It Slow Kidney Growth and Disease Progression? GLP1 Clinical Trial: Glucagon-Like Peptide-1 Receptor Agonist in ADPKD FLOW Trial: https://pubmed.ncbi.nlm.nih.gov/38785209/ Support the Show: patreon.com/PKDDietitian WORK WITH DIANA: thepkddietitian.com/workwithme HAVE A QUESTION? Send a message to info@thepkddietitian.com FIND THE PKD DIETITIAN ONLINE Patreon: PKDDietitian Instagram: @The.PKD.Dietitian Facebook: The PKD Dietitian Website: thepkddietitian.com Support the show and access future bonus content and deeper PKD nutrition insights: patereon.com/PKDDietitian DISCLAIMER The PKD Dietitian Podcast is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Linktree for Community ResourcesNeed help appealing a GLP-1 Insurance Denial? FindHonestCare.com/KimRo - Telehealth for GLP1 Weight ManagementThe Absolute Lies You've Heard About GLP-1s (Ozempic Myths Debunked) [REPLAY]Are you being lied to about Ozempic, Mounjaro, and Wegovy? In this special replay episode, leading obesity medicine specialists break down the biggest GLP-1 myths taking over your feed. We are reposting this crucial conversation because it is more relevant than ever. With GLP-1 price changes and expanding access options through federal programs like the Medicare GLP-1 Bridge, understanding the real science behind these medications is essential for patient advocacy.We are sharing a few favorite replay episodes right now while Kim is away on bereavement leave following the loss of her sister. We want to deeply thank our subscribers for staying engaged and supporting the show during this time.In this episode of The Plus Sidez Podcast, Kat joins Kim to sit down with obesity medicine specialists Dr. Matea Rentea and Dr. Ali Novitzki to help listeners better understand their disease and feel empowered in their healthcare journey.The Myths We Debunk:The Muscle Loss Scare: The data behind weight loss and body composition, explaining why the medication itself is not destroying your lean mass.The Willpower Narrative: Why obesity is a genetic, chronic metabolic disease rooted in brain biology, not a failure of personal willpower.The Shot-Only Illusion: How the medication works alongside your body's natural satiety signals and gut receptors.Obesity Doctor Guidance Shared:Metabolic Protection: A practical discussion on utilizing a 10-minute fitness routine and a 100-gram protein framework to maintain lean mass and support insulin sensitivity.System Navigation: Insights on navigating insurance barriers, managing prior authorizations, and advocating for proper medical care.Mental Resilience: Tools to process unsolicited comments about your weight and protect your peace from societal judgment.Episode Topics:Why We Are Replaying This Episode: Prices, Access, and UpdatesThe Insurance Landscape: Understanding Prior AuthorizationsMeet the Obesity Medicine SpecialistsDeconstructing the GLP-1 Muscle Loss NarrativeStrategies for Protecting Your MetabolismWhat the Scales Do Not Show About Insulin ResistanceNatural Satiety Triggers and Gut ReceptorsRecognizing Obesity as a Biological Chronic DiseaseAddressing Weight Stigma and External CommentarySubscribe to The Plus Sidez Podcast for science-backed episodes breaking down metabolic health, body recomposition, and the truth about weight loss.Search TagsGLP1 lies debunked, Ozempic myths, Mounjaro weight loss journey, Wegovy truth, Zepbound body recomposition, insulin sensitivity hacks, natural GLP1 boosters, treating obesity metabolic disease, plus sidez podcast, dr matea rentea, dr ali novitzki_________________________________________________________________________Join this channel to get access to perks:https://www.youtube.com/channel/UC0HUIGKl3BN4Vg6LYI-dkOA/join_________________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovySend us Fan Mail!Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)What If the Lowest Dose Isn't Actually the Safest Dose?If you've spent any time in weight loss or wellness spaces online, you've probably come across the term microdosing — and chances are, it was framed as the smarter, gentler, more mindful way to use GLP-1 medications. But is that actually true? That's exactly what we're digging into today.In this episode, we cover:Is "Microdosing" GLP-1s Actually a Thing? — Where the term came from, why it took off, and whether it holds up clinically.The Right Dose Is the One That's Actually Working for You — What therapeutic dosing actually means and how to know if yours is doing its job.Weight Loss Is a Side Effect, Not Always the Goal — Why the scale isn't the only thing worth tracking — and what to measure instead.There Is No Prize for the Lowest Dose — The real cost of staying subtherapeutic and why "less is more" doesn't always apply here.There is no prize for taking the lowest dose. The goal isn't to stay as low as possible, and it isn't to push as high as possible either. The goal is to find the dose that actually works for you — for your body, your health conditions, and your specific outcomes. Check out the full episode and give it a listen — it's worth your time.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

One of the biggest questions people ask about GLP-1 medications is:“What happens if I stop taking it?”Whether you're taking Ozempic, Wegovy, Mounjaro, or Zepbound, you may have concerns about losing insurance coverage, reaching your goal weight, medication costs, long-term use, or the possibility of regaining weight in the future.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down what the research actually shows about stopping a GLP-1 medication, the factors that influence weight regain, and what you can start doing now to support long-term success.We're covering:What happens when you stop a GLP-1 medicationWhether weight regain is inevitableWhy hunger and food noise may change after discontinuationCommon myths about stopping Ozempic, Wegovy, Mounjaro, and ZepboundWhy willpower is not the solutionThe habits that support long-term weight maintenanceWhat to do if you lose access to your medicationHow to think about weight regain without shame or fearIf you've ever worried about what happens after a GLP-1, this episode will help you approach the conversation with more knowledge, less fear, and a realistic plan for the future.

A headline like “weight loss drugs may reduce breast cancer risk” grabs attention fast, but the real story lives in the fine print. We take you through a new Penn Medicine study that observed lower breast cancer rates among women with overweight or obesity who used GLP-1 medications, then we translate what that finding actually means in plain language. Observational data can reveal a signal worth studying, but it cannot prove the medication caused the outcome, and that distinction matters for your decisions and your expectations. We also zoom out to the bigger why: obesity is not just about body size. Fat tissue is biologically active, shaping chronic inflammation, estrogen exposure after menopause, insulin resistance, and even how well the immune system spots abnormal cells. Those pathways help explain why obesity is linked to many cancers, including postmenopausal breast cancer, and why researchers are curious whether effective obesity treatment could shift risk over time. Then we get practical. We review what stronger evidence from randomized controlled trials says so far: GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound do not appear to increase breast cancer risk in the available trial data, even though most trials were not designed to study cancer outcomes for many years. We also discuss why newer studies seem most suggestive for hormone receptor positive breast cancer, along with the leading theories: weight loss itself, improved metabolic health and insulin signaling, reduced inflammation, and the still-unclear possibility of direct GLP-1 effects in cancer biology. If you like evidence-based medicine with real-world context (and a little Philly-life banter), subscribe, share this episode with a friend, and leave a review so more people can find the show. What question do you want answered next about GLP-1s, obesity treatment, or cancer risk?ReferencesRisk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-Analysis. Ko A, Chang YC, Bahar F, et al. Annals of Internal Medicine. 2025;. doi:10.7326/ANNALS-25-02237.Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis. Piccoli GF, Mesquita LA, Stein C, et al. The Journal of Clinical Endocrinology and Metabolism. 2021;106(3):912-921. doi:10.1210/clinem/dgaa891.Glucagon-Like Peptide 1 Receptor Agonists and Cancer Risk: The Good, the Bad and the Unknown. Mannucci E, Dicembrini I. Nature Reviews. Clinical Oncology. 2026;23(6):459-470. doi:10.1038/s41571-026-01135-0.GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women. McDonald ES, Gillis LB, Gabriel P, et al. JCO Oncology Practice. 2026;:101200OP2600485. doi:10.1200/OP-26-00485.GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.. Shah Z, Hundal J, Afridi S, et al. Journal of Clinical Oncology. 2026;44(Suppl 16):10548. doi:10.1200/JCO.2026.44.16_suppl.10548.Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer. Tatum KL, Dahman B, Stevenson A, et al. JAMA Network Open. 2026;9(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133.Association of Glucagon-Like Peptide-1 Receptor Agonists With Risk of Cancers-Evidence From a Drug Target Mendelian Randomization and Clinical Trials. Sun Y, Liu Y, Dian Y, et al. International Journal of Surgery (London, England). 2024;110(8):4688-4694. doi:10.1097/JS9.0000000000001514.GLP-1 receptor agonists and breast cancer risk in type 2 diabetes.. Guo Cheng and Amanda Ward. Journal of Clinical Oncology. 2025;43(Suppl 16):10557. doi:10.1200/JCO.2025.43.16_suppl.10557.Glucagon-Like Peptide-1 Analogues and Risk of Breast Cancer in Women With Type 2 Diabetes: Population Based Cohort Study Using the UK Clinical Practice Research Datalink. Hicks BM, Yin H, Yu OH, et al. BMJ (Clinical Research Ed.). 2016;355:i5340. doi:10.1136/bmj.i5340.GLP-1 Receptor Agonists and Cancer: Current Clinical Evidence and Translational Opportunities for Preclinical Research. Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. The Journal of Clinical Investigation. 2025;135(21):e194743. doi:10.1172/JCI194743.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

What happens to bariatric surgery when GLP-1 medications like Ozempic, Wegovy, and Zepbound change the entire weight loss landscape?In this episode, Dr. Matthew Weiner and registered dietitian Zoe unpack what they saw at the 2026 ASMBS annual conference - a meeting that felt very different from prior years. Surgical volumes are down, many bariatric surgeons are wrestling with what GLP-1s mean for their practices, and patients are left trying to figure out whether medication, nutrition, surgery, or some combination makes the most sense.Dr. Weiner explains why bariatric surgery still matters, but no longer belongs in the same place in the treatment sequence. For many patients, a GLP-1 trial should come first. For others, especially non-responders, patients with severe diabetes, or people losing mobility, surgery may be the safest and most effective next step.They also discuss why low-dose GLP-1s may be more sustainable than high-dose treatment, how to recognize a medication non-response, and why the best obesity care in 2026 combines nutrition, medication, surgery, and long-term support instead of forcing patients into one silo.

DC EKG with Joe GroganThe Economics of Ozempic and Other Weight Loss DrugsEpisode 136.5 (“Prescription Refill” – A replay from the archives)Original Air Date: May 2024In this episode, Joe Grogan welcomes Ben Ippolito, Senior Fellow in Economic Policy Studies at the American Enterprise Institute, to discuss the rapidly evolving economics of GLP-1 weight loss drugs like Ozempic and Wegovy.Ben explains the two main competitors in this market—Novo Nordisk's Ozempic and Wegovy versus Eli Lilly's Mounjaro and Zepbound. Revealing how insurance coverage decisions drive pharmaceutical marketing strategy.The conversation reveals a critical irrationality in Medicare policy: the statutory prohibition on covering weight loss drugs despite their profound clinical and quality-of-life benefits. Yet these same drugs are covered for diabetes and cardiovascular risk reduction.Ben explores the surprising economics of drug pricing through gross-to-net pricing—the massive gap between list prices and what insurers actually pay through rebates and discounts.The episode examines critical implications of the Inflation Reduction Act's price negotiation provisions. Once Medicare negotiates Ozempic's price, that same price applies to all products using the same active ingredient. This creates cascading market effects: competitors must match those prices to remain on formularies, new entrants face lower pricing power even if clinically superior, and pharmaceutical companies may abandon promising programs due to regulatory uncertainty.Ben argues Congress doesn't need to act immediately to expand Medicare coverage, but likely will within a few years.Joe and Ben discuss unintended consequences of government price regulation, including effects on innovation and drug development pipelines. They explore how price controls announced before elections affect pharmaceutical strategy and development timelines.Concluding with Ben's research on Medicare Advantage and why both Democrats and Republicans scrutinize this private alternative to traditional Medicare. With over 50 percent of seniors enrolled in Medicare Advantage plans, bipartisan interest in reform is reshaping healthcare policy conversations on Capitol Hill.Key TopicsGLP-1 drugs, Ozempic, Wegovy, Mounjaro, Zepbound, weight loss medications, obesity treatment, Medicare coverage, drug pricing, Inflation Reduction Act, pharmaceutical competition, rebates, gross-to-net pricing, health economics, cardiovascular benefits, diabetes treatment, Medicare Advantage, healthcare policy, innovation incentivesKey Timestamps00:00 Cold Open: "Turned Up to 11"00:24 Welcome to DC EKG00:46 Meet Ben Ippolito (AEI)03:48 The GLP-1 Landscape: Ozempic, Wegovy, and the Field05:04 One Drug, Two Names06:45 Medicare's Weight-Loss Coverage Ban07:21 Blockbusters and Big Effect Sizes09:32 Why Isn't Congress Acting?10:17 Why It Costs Less Than You Think12:34 The Coverage Irrationality14:05 Quality of Life as a Real Benefit15:17 Beyond Weight: Cravings and Addiction18:21 Devil's Advocate: Why Cover It At All?19:48 Gross-to-Net and the Rebate Problem22:41 Why Can't You Just Pay Cash?25:43 The IRA and the Ozempic Price Cut27:32 One Ingredient, One Price30:10 Unintended Consequences in Part D34:01 New Competitors and Killed Programs38:03 What's Next: Medicare Advantage42:04 Wrap-Up and CreditsAbout the Guest(As of May 2024) Ben Ippolito is a Senior Fellow in Economic Policy Studies at the American Enterprise Institute. He holds a PhD and Master's degree in Economics from the University of Wisconsin-Madison and a Bachelor's degree in Mathematics and Economics from Emory University. Ben examines drug pricing policy, Medicare Advantage, and healthcare innovation economics with regular engagement with Congress.Podcast: DC EKG with Joe GroganGuest: Ben IppolitoSponsor: Survivors for SolutionsProducer: Stay on Course StudiosExecutive Producer: John CZ Czwartacki, DC EKG Podcast

Nutritionist Leyla Muedin discusses research showing simple strength tests—grip strength and a five-rep sit-to-stand chair test—predict longevity in older women. In a University at Buffalo study of over 5,000 women ages 63–99 followed for eight years, stronger grip and faster chair-stand times were linked to lower mortality; every additional 7 kg of grip strength corresponded to a 12% reduction in death risk, and faster chair-stands were also associated with improved survival, even after adjusting for activity, cardiovascular fitness, and inflammation. She emphasizes prioritizing muscle-strengthening alongside aerobic exercise and suggests accessible resistance options (weights, bodyweight moves, or household items) with professional guidance as needed. She then cites UK Biobank data linking long-term statin use to declines in grip strength and appendicular lean mass, urging discussion with physicians and added vigilance, especially for those also using GLP-1 drugs that may reduce protein intake and muscle mass.

In this episode, I'm talking honestly about weight loss burnout. The mental exhaustion that comes from constantly thinking about food, planning meals, trying to “be good,” starting over, tracking, and feeling like your body is always a project that needs fixing.I also share what this experience has been like for me while being on Tirzepatide. The food noise is quieter, but now I find myself in this strange in-between space where I'm hungry, but nothing sounds good. I take a few bites and feel full… while somehow still feeling hungry at the same time. And honestly? I'm tired.This episode isn't anti-weight loss. It's about what happens when your entire life starts revolving around shrinking yourself, and the realization that maybe peace matters too.Because you deserve a life bigger than calorie counting.Show Notes

It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcripts: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We'll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We've got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind's afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients.   The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: "Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option." Lots more to come on this – we're working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. https://www.massdevice.com/mannkind-fda-approval-inhaled-insulin-children/ XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it's such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They're calling this Libre Duo and Libre Duo 10 Day, and it's designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes   XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery  with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic.   Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action.   The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling.   Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said.   People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX   Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics' interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association's Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet's patch pumps on the market. It would have a 200-unit insulin reservoir.   Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall.   https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it's coverage list – with it's Caremark PBM. They also added Foundayo, Lilly's obesity pill. CVS had dropped Lilly's Zepound last summer but kept competitor Wegovy. It'll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers ​now cover Lilly's full obesity medicine portfolio. https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/   More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers.   Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). "Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence," the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women.   Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea.   While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. "Tidepool has always focused on making diabetes data more accessible and actionable," said Brandon Arbiter, CEO. "We're excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters."   Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool's existing EHR integration capabilities.   Direct Connect is part of Tidepool's ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes.   The feature is now available in the Connection Hub of the Epic Showroom.   https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel Skowronski, who suggested that obesity could become a solved disease within just a few generations of innovation.What does that mean for the millions of patients still fighting for access to GLP-1 medications like Zepbound, Mounjaro, and tirzepatide? And what is Lilly seeing in its pipeline that the rest of us can't?We dig into:Lilly's decision to stop disclosing its Phase 1 pipelineThe Camurus fluid crystal technology deal and what it means for long-acting GLP-1sEloralintide — Lilly's selective amylin agonist and potential dark horse in obesity medicineHow eloralintide compares to Novo Nordisk's cagrilintideWhy the future of obesity treatment is a toolbox, not a scoreboardThe access crisis: prior authorizations, insurance exclusions, Medicare, and Medicaid coverage gapsRetatrutide, quintuple agonists, and what's coming out of ADA 2026If you're on Zepbound, Wegovy, Ozempic, or any GLP-1 medication — or you're waiting for the next generation of obesity drugs — this episode is for you.

GLP-1 weight loss is about so much more than just the number on the scale.If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound and feeling emotionally overwhelmed, anxious, conflicted, or even surprised by how much this journey is affecting your mindset—you are not alone.In this episode, Registered Dietitian and GLP-1 expert Gianna dives into the mental and emotional side of GLP-1 weight loss that almost nobody talks about.We're covering:How GLP-1 medications can change your relationship with foodWhat “food noise” is and why reduced food thoughts can feel emotionalWhy body image struggles don't automatically disappear with weight lossThe pressure of social media transformation cultureFear of weight regain and “what if this stops working?” thoughtsWhy needing a GLP-1 does not mean you failedIdentity shifts that can happen during major body changesHow to build a healthier mindset around sustainable weight lossWhether you're newly starting Ozempic, Wegovy, Mounjaro, or Zepbound—or deep into your GLP-1 journey—this episode is a reminder that your mental health matters too.Because sustainable health is not just about shrinking your body. It's about supporting your whole self.

In this episode, we break down the science behind GLP-1 medications including Ozempic, Wegovy, Zepbound, Mounjaro, semaglutide, and tirzepatide. Learn how GLP-1 weight loss medications work, their role in appetite suppression, insulin regulation, metabolic health, obesity treatment, and type 2 diabetes management.This evidence-based discussion explores GLP-1 benefits, side effects, muscle loss concerns, weight regain after stopping medication, nutrition considerations, digestion, metabolic adaptation, and sustainable wellness strategies. If you're considering GLP-1 medications or simply want a smarter conversation about obesity medicine, weight loss, longevity, and metabolic health, this episode delivers a clinically grounded wellness perspective. Disclaimer: This podcast is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The views shared are intended to support informed wellness conversations and should not replace individualized guidance from your physician or qualified healthcare provider. Always consult your healthcare team before making decisions regarding medications, treatment, nutrition, or health management.

Tirzepatide, marketed as Zepbound, mimics the action of GLP-1 and GIP, two hormones naturally released by your gut. These hormones are critical in regulating appetite and how much food you consume. By enhancing the feeling of fullness and reducing hunger, tirzepatide helps support weight loss. Read the Full Episode Transcript: https://pepties.com/common-questions-of-tirzepatide/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ Buy Peptides online at BioLongevity Labs: Use our link and enter COUPON CODE: PEPTIDEPODCAST  at checkout to receive 15% off your total order:  https://go.biolongevitylabs.com/SH5C Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

GLP-1 medications like Ozempic, Mounjaro, and Zepbound are changing the conversation around obesity and weight loss — but there's one major problem: most people are starting these medications with little to no guidance on how to properly nourish their body while taking them.And that matters.Because while GLP-1s can be incredibly effective tools for weight loss, they can also lead to muscle loss, under-eating, fatigue, nausea, hair loss, and long-term metabolic issues when nutrition is neglected.In today's episode, I'm breaking down the biggest nutrition mistakes people make on GLP-1 medications — and exactly how to protect your metabolism, preserve muscle, maintain energy, and build sustainable habits while losing weight.We'll cover:- Why protein becomes non-negotiable on GLP-1 medications- How much protein you actually need- The hidden dangers of under-eating- Why rapid weight loss can harm your metabolism- How to preserve muscle while losing fat- The critical role of strength training- What to do if you have no appetite- Tips for nausea and food aversions- How to create sustainable eating habits while on GLP-1s- Rebuilding a healthier relationship with foodThis episode is especially important if you've ever thought:“I'm barely eating… so why do I feel exhausted?”“Why am I losing muscle instead of just fat?”“How do I hit my protein goals when I'm never hungry?”GLP-1 medications are not magic — but when combined with proper nutrition and lifestyle support, they can become powerful tools for long-term health.If you're currently taking a GLP-1 medication, considering one, or supporting someone who is, this episode is a must-listen.And if you're looking for support along your journey, Dr. Sasha High and I would love to welcome you into our women's coaching program, Best Weight, where we openly discuss treatment options like GLP-1 medications and help women build sustainable, healthy weight loss habits together. WORK WITH US:O​​ntario-Wide Virtual Obesity Management Clinichttps://www.highmetabolicclinic.comJoin my Weight Loss Coaching Program for women, Best Weight https://www.sashahighmd.com/bestweightRecover Strong for Binge Eatinghttps://www.sashahighmd.com/bedTaking the first step toward weight loss can feel overwhelming — but you don't have to do it alone. I've created a curated list of my podcast episodes to gently guide you as you begin your journey. https://www.sashahighmd.com/podcast-guideFOLLOW SASHAInstagramhttps://www.instagram.com/sashahighmd/ADDITIONAL RESOURCES:BMI CalculatorBasal Metabolic Rate Calculator(BMR) REFERENCES:Carbone, J. W., & Pasiakos, S. M. (2019). Dietary Protein and Muscle Mass: Translating Science to Application and Health Benefit. Nutrients, 11(5), 1136. https://doi.org/10.3390/nu11051136 McCarthy, D., & Berg, A. (2021). Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss. Nutrients, 13(7), 2473. https://doi.org/10.3390/nu13072473 Scott Butsch, W., Sulo, S., Chang, A. T., Kim, J. A., Kerr, K. W., Williams, D. R., Hegazi, R., Panchalingam, T., Goates, S., & Heymsfield, S. B. (2025). Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study. Obesity pillars, 15, 100186. https://doi.org/10.1016/j.obpill.2025.100186

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent updates offer a fascinating glimpse into an industry marked by dynamic shifts and groundbreaking advancements, each promising to reshape the future of healthcare. Let's delve into some of the most notable developments that are capturing attention across the globe. Starting with Eli Lilly's obesity medication, Zepbound, which has regained insurance coverage through CVS Caremark. This decision is emblematic of a broader recognition of obesity as a significant health issue that demands comprehensive treatment solutions. The reinstatement of coverage enables more patients to access Zepbound, potentially setting a benchmark for other insurers and leading to improved health outcomes. Shifting focus to oncology, AbbVie has secured FDA approval for a new therapy derived from its acquisition of ImmunoGen, adding to its portfolio of antibody-drug conjugates (ADCs) with Elahere. This development underscores the escalating value of ADCs in precision cancer therapies, offering innovative solutions for targeting cancer cells while preserving healthy tissues. Japan's pharmaceutical R&D stance is under examination as Prime Minister Sanae Takaichi meets with over 20 industry leaders to discuss maintaining the nation's competitive edge. This gathering highlights a global race among nations to enhance their R&D capabilities, ensuring leadership in pharmaceutical innovations. In neuroscience, Novartis's relentless pursuit to conquer the blood-brain barrier reflects ongoing efforts to revolutionize treatments for neurological disorders. Despite recent advancements, Novartis continues to explore new strategies for drug delivery to the brain, aiming to unlock therapies for conditions like Alzheimer's and Parkinson's disease. Viridian Therapeutics' collaboration with Wuxi Biologics marks a notable push in the eye drug market, positioning them against major players like Amgen. This partnership emphasizes manufacturing capability as a critical factor in ensuring resilient supply chains and competitive advantage. The hepatitis B treatment landscape has witnessed significant progress with GSK's phase 3 trial results for its drug Bepirovirsen. Achieving a functional cure in around one-fifth of patients signifies a major step forward in addressing this widespread disease. The potential to reduce lifelong antiviral therapy and lower liver cancer rates illustrates the transformative impact of nucleic acid-based therapies. Leadership dynamics also play a crucial role in pharma strategies. PharmaEssentia's appointment of Eric Vogel highlights the industry's reliance on seasoned talent to drive market expansion and broaden therapeutic indications, particularly for its rare blood cancer drug Besremi. In longevity research, Human Longevity's collaboration with Insilico Medicine introduces Human Life Foundation Models (HLFM), leveraging AI and genomics to extend human lifespan. This initiative is part of a broader trend integrating cutting-edge technologies into healthcare research, reflecting an evolving focus on longevity and genomic sciences. Regulatory landscapes are also evolving, as seen with CMS finalizing changes to the No Surprises Act dispute resolution process. By streamlining arbitration amidst rising disputes, these updates aim to refine healthcare policy frameworks for more efficient stakeholder service. Meanwhile, biosimilar approvals are gaining traction globally. ANVISA's approval of EMS's Ozivy in Brazil introduces a cost-effective alternative to Novo Nordisk's semaglutide (Ozempic) for type 2 diabetes. This step enhances access to affordable diabetes treatments, crucial for managing this prevalent metabolic disorder. In clinical trials innovation, D&D Pharmatech's Zabopegdutide has shown promising Phase 2 results for metabolic dysfunction-associated steatohepatitis (MASH), indicating fibrosis improvement and potential disease resolution. These findings underscore dual receptor agonists' therapeutic promise in tackling complex metabolic conditions. Additionally, Kailera Therapeutics' KAI-4729 demonstrates significant weight loss in Phase 1 obesity trials, potentially reshaping the obesity treatment landscape by offering superior weight management options compared to existing therapies. Funding rounds like Secretome Therapeutics' successful $30 million Series A highlight ongoing investments in regenerative medicine and cell-based therapies, propelling advancements in cardiovascular disease treatment pipelines. The acquisition landscape remains active with CordenPharma's purchase of AmbioPharm, expanding peptide manufacturing capabilities across U.S. and China markets. This move meets growing demand for peptide APIs vital in drug development processes. Technological innovation remains pivotal as Biohub releases an AI World Model for protein biology to expedite therapeutic discovery processes. This tool exemplifies computational biology's integration into drug discovery efforts, enhancing efficiency and innovation. Overall, these developments illustrate a vibrant pharmaceutical and biotech landscape characterized by scientific breakthroughs, strategic partnerships, regulatory achievements, and technological advancements—all aimed at advancing patient care and expanding therapeutic possibilities across diverse medical domains. As these trends continue unfolding, they promise not only improved treatment outcomes but also a more robust global healthcare ecosystem committed to innovation and excellence. Thank you for tuning into Pharma Daily; stay informed as we continue bringing you the latest from this rapidly evolving industry.Support the show

SUMMARY DEL SHOW Futuros con ligera presión antes del PCE, con el crudo repuntando por nuevos incidentes en Ormuz y la narrativa volviendo a energía, tasas y Fed. $SNOW se dispara tras cerrar un acuerdo a cinco años con AWS para asegurar acceso a Graviton, una señal de “capacidad garantizada” en plena explosión de demanda por AI. Drones se recalientan por el plan “Drone Dominance” y $CVS decide volver a cubrir Zepbound de $LLY en parte de sus listas, subiendo la competencia frente a $NVO.

Dr. Michael Stubblefield is a cancer rehabilitation expert and Dr. Joseph Dayan is a plastic and reconstructive surgeon who has pioneered techniques to ease lymphedema with surgery. They're both very interested in how the GLP-1 medicines, like Ozempic, Wegovey, Zepbound, Mounjaro, Victoza, and Trulicity — just to name a few — could be used to manage lymphedema. Listen to the episode to hear Drs. Stubblefield and Dayan explain: how common lymphedema is among people with breast cancer current lymphedema treatments how the new study using a GLP-1 medicine to treat lymphedema came about what we know right now about GLP-1 medicines and breast cancer treatments

Mazel morons! This week, we're back at you with the original recipe and we're coming in hot. From millennial parents sipping Mai Tais in the dugout , to a Knicks away game and a suite full of Hasidic Jews, we're recapping our Mother's days and thoughts on etiquette across the board. Plus, we're getting real about the Zepbound blues and consulting a cheese witch to read our future in a block of cheddar. What are ya nuts? Love ya! Write us! goodguyspodcast1@gmail.com Follow us on Instagram and TikTok!  Please note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode. Produced by Dear Media. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dealing with constipation, nausea, or bloating on a GLP-1 like Ozempic, Wegovy, Mounjaro, or Zepbound?You are definitely not alone.Digestive side effects are some of the most common challenges people experience on GLP-1 medications—but there's a huge difference between expected side effects and feeling miserable all the time.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down the science behind GLP-1 digestive side effects, including why they happen, what evidence-based strategies can actually help, and the biggest mistakes that may be making symptoms worse.We're covering:Why GLP-1 medications can cause constipation, nausea, and bloatingHow delayed gastric emptying impacts digestionWhy under-eating can actually worsen side effectsWhat to eat when nausea makes food unappealingEvidence-based strategies for constipation reliefHow hydration and meal structure affect symptomsThe truth about fiber on GLP-1sWhen side effects are no longer considered “normal”The social media advice you should probably ignoreWhether you're taking Ozempic, Wegovy, Mounjaro, or Zepbound, this episode will help you better understand what's happening in your body—and how to support your digestion without extreme restriction or fear.

What happens when Amazon turns weight loss into a one-click purchase?This week on Slay, Louise Hazel breaks down the shocking news that Amazon is stepping into the GLP-1 market—making medications like Ozempic, Wegovy and Zepbound more accessible than ever before.But beneath the headlines lies a bigger question:Are women becoming healthier… or simply thinner?In this episode: ✓ What Amazon's GLP-1 launch means✓ Why millions more women may start taking weight-loss drugs ✓ The hidden muscle loss crisis nobody is talking about ✓ How pharmaceutical pressure may reshape body image ✓ Why strength training matters now more than everThis is not anti-GLP-1.This is pro-informed women.Because no injection replaces muscle.No shortcut replaces strength.The future belongs to strong women.Comment APP and I'll DM you the waitlist link for the new Slay app—your new strength companion.#SlayPodcast #GLP1 #Ozempic #WomenHealth #StrengthTraining #FitnessNews #LouiseHazel #WomenWhoLift #HealthyWeightLoss #Amazon

Three new GLP-1 studies, why every food is suddenly "high protein," the Bethenny Frankel shoe drama blowing up Instagram, and why I'm on a ketamine table as you listen. Three new studies just shifted the GLP-1 conversation, and not in the direction women have been hearing about. Chalene digs into what's actually happening to muscle and bone density, why the rebound after coming off matters more than anyone's talking about, and the three questions every woman on Ozempic, Wegovy, Mounjaro, or Zepbound should bring to her next doctor's appointment. She also gets into why every grocery aisle suddenly screams "high protein," and why this whole moment is starting to feel suspiciously like the Snackwell cookie era. There's a simple protein target that works without tracking macros, and Chalene walks through how she's using it. Then she breaks down the Bethenny Frankel shoe drama that took over Instagram this week. What the shoe brand founder got wrong, what Bethenny got wrong, and the rules of brand partnerships that almost nobody outside the influencer world understands. Finally, a personal update. As you're listening to this, Chalene is on the table for another medically supervised ketamine treatment with Dr. Andrew Levinson. She shares why she went back for a third session, what the last journey taught her about control, and who this kind of work is really for.  

The vast majority of employer health plans do not cover GLP-1s for weight loss. But roughly 20% do, many believing it will help their bottom line. Perhaps when employees take Wegovy or Zepbound, they'll need less medical care tied to health issues from obesity. Today on the show, can GLP-1s save employers money in the long run?Fact checking by Sierra Juarez.Your Next Listen — No healthcare premiums? In this economy?! Here's how.— Julie Wernau's original episode with TradeoffsConnect with The Indicator — Sign up for The Indicator's brand new newsletter— Find our socials, YouTube and more!— For sponsor-free episodes, subscribe to NPR+ See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy

Colorectal cancer is now the leading cancer killer in adults under 50, and patients in their 20s are presenting with metastatic disease that has nothing to do with family history. Most physicians are still telling young patients with rectal bleeding that it's probably just hemorrhoids and that's costing lives.In this episode, Dr. Gabrielle Lyon sits down with Dr. Michelle Pearlman, a board-certified gastroenterologist and founder of a Miami-based gastro-metabolic clinic, to discuss:The specific warning signs every adult under 50 should never ignore, regardless of age including rectal bleeding, unintentional weight loss, and persistent abdominal painWhy GLP-1 medications like Ozempic and Zepbound are being miscategorized as weight loss drugs when they're actually metabolic reprogrammers with applications in fatty liver, sleep apnea, and inflammationThe protein, fiber, and resistance training protocol Dr. Pearlman uses to protect muscle mass in patients on GLP-1 therapyHow hormone replacement therapy combined with GLP-1s is changing body composition outcomes for perimenopausal women and why current guidelines are still 20 years behind the dataDr. Pearlman's personal osteoporosis diagnosis at 39, despite being a lifelong bodybuilder, and what it revealed about the diagnostic gaps in standard medicineThis conversation gives you the framework to recognize the warning signs most physicians are still missing, and the foundational habits; nutrition, resistance training, and hormone optimization that protect your gut, bones, and muscle through midlife and beyond.Thank you to our sponsors: Cozy Earth - Go to https://bit.ly/4teXQhz for up to 20% off! Timeline - Get 20% off your Mitopure order at https://bit.ly/4eLBWhB Lucy - Get 20% off your next order with code DRLYON at https://bit.ly/42HiUlc, or find yours in store at https://bit.ly/3RfGnYa Amp - Visit https://bit.ly/3RcmqBz to get your AI-powered at-home gym for smarter, personalized training.Explore More from Dr. Gabrielle LyonPremium Podcast Subscription: Ad-free episodes, key takeaway summaries, exclusive Q&A, and behind-the-scenes content https://foreverstrong.supercast.comWeekly newsletter: Recipes, podcast updates, and practical weekly insights https://drgabriellelyon.com/sign-up/Apply to become a patient: Personalized care with Dr. Lyon's clinical team https://drgabriellelyon.com/new-patient-inquiry/Find Dr. Michelle Pearlman at:Instagram: https://www.instagram.com/michellepearlmanmd/ Website: https://pearlmanmds.com/michelle-pearlman-md/ Connect with Dr. Gabrielle LyonInstagram: https://www.instagram.com/drgabriellelyon/TikTok: https://www.tiktok.com/@drgabriellelyonX (Twitter): https://x.com/drgabriellelyonFacebook: https://www.facebook.com/doctorgabriellelyonChapters00:00 - Introduction: Colorectal cancer under 5001:15 - The gastro-metabolic approach explained03:30 - Why nutrition isn't taught in GI fellowship05:45 - When the colonoscopy is normal but patients suffer07:00 - Weight, reflux, and visceral fat09:15 - PPIs, bone density, and long-term risk11:30 - Three things to never do for gut health14:00 - Ultra-processed food and early-onset cancer16:45 - Rectal bleeding, warning signs, and age19:00 - Screening guidelines and the obesity gap22:30 - GLP-1 medications: history and mechanism27:15 - Hunger, cravings, and food noise30:00 - The stigma around metabolic medications33:45 - Side effects: nausea, reflux, constipation38:30 - Compounded formulations and pharmacy safety42:00 - Hair loss, protein, and supplementation45:15 - Pill versus injection delivery systems49:30 - Fiber, the microbiome, and short-chain fatty acids54:00 - GLP-1s plus hormone replacement therapy58:45 - Testosterone, Kyzatrex, and women's bone health1:03:00 - Pearlman's osteoporosis diagnosis at 391:09:30 - The diagnostic gap in standard medicine1:14:00 - Building Bite MD and the future of nutrition tech Disclaimers: This episode includes paid sponsorships. The Dr. Gabrielle Lyon Podcast and YouTube are for general information purposes only and do not constitute the practice of medicine, nursing, or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast, YouTube, or materials linked from this podcast or YouTube is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professional for any such conditions.

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

Noticing more hair shedding since starting a GLP-1 like Ozempic, Wegovy, Mounjaro, or Zepbound?You are not alone—and despite what social media might say, there's a lot of misinformation about hair loss on GLP-1 medications.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down the science behind hair loss and rapid weight loss, including what current evidence actually suggests about why shedding may happen during a GLP-1 journey.We're covering:Whether GLP-1 medications directly cause hair lossHow rapid weight loss can impact the hair growth cycleWhat telogen effluvium is and why it mattersThe connection between low protein intake and hair sheddingWhy under-eating can make symptoms worseNutritional factors that may play a role in hair healthWhen to talk to your healthcare provider about symptomsThe biggest mistakes people make when hair shedding startsIf you've been feeling anxious, overwhelmed, or frustrated by changes in your hair while taking Ozempic, Wegovy, Mounjaro, or Zepbound, this episode will help you better understand what may be happening in your body—and what to focus on moving forward.

People keep asking the same question: what's actually the difference between all these weight loss medications?  Ozempic. Wegovy. Mounjaro. Zepbound. Foundayo. Wegovy pill. Some of these medications are injections, some are pills, some are FDA-approved for diabetes, others for weight loss, and some are actually the same medication with completely different brand names. So I'm breaking it all down for you today — in plain language — because the confusion alone is keeping people from getting the treatment they need. The real problem isn't just the brand names. It's that without knowing exactly how these medications differ, patients end up on the wrong one, pay out of pocket unnecessarily, or give up when insurance denies them. You deserve better than that. Once you understand what each one actually does, the whole picture becomes much clearer. Listen now!   Episode Highlights: Why Ozempic and Wegovy are the same medication and why the difference still matters How tirzepatide (Mounjaro/Zepbound) works on two hormone pathways and why it tends to produce greater weight loss The new oral options — Foundayo and Wegovy pill — and who they're actually right for Real average weight loss numbers from clinical trials, by medication How insurance covers (or denies) each one and what I tell my patients when it does Who may be a candidate for these medications   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

This week, This Week in Pharmacy examines several stories shaping the business, clinical, and legal future of pharmacy practice. In TWIRx News from Pharmacy Times from Megan Maroney, PharmD, BCPP, FAAPP, focused on antidepressant use, withdrawal concerns, deprescribing, and shared decision-making. The key takeaway: patients should never stop antidepressants abruptly. Pharmacists can play a vital role in reducing stigma, educating patients, and supporting safe conversations about tapering, side effects, and long-term treatment. In health technology news, FDB research presented at the 2026 AMIA Amplify Informatics Conference found that patient-specific, risk-based medication guidance reduced pharmacy alert volume by 70% in a high-volume community pharmacy setting. The model consolidates alerts into one actionable message tied to the patient's most relevant risk, helping reduce alert fatigue and improve workflow. Finally, we review a federal court ruling in Eli Lilly's lawsuit against Houston-based Empower Pharmacy over compounded tirzepatide versions of Mounjaro and Zepbound. The judge dismissed key federal trademark and Texas unfair competition claims, while allowing other state claims to continue. Andy Crawford, with Keysource is back on TWIRx talking about the U.S. Supreme Court taking up Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., a case that could significantly affect generic drug competition. At issue is whether Hikma's marketing materials and public communications around its generic version of Amarin's fish oil-based cardiovascular drug improperly promoted a still-patented use. Hikma and the broader generic industry argue the case is about protecting “skinny label” rules, which allow generics to carve out patented indications while still bringing lower-cost medications to market. For pharmacists, the decision could influence generic availability, substitution confidence, pricing pressure, and how manufacturers communicate with providers and pharmacies. Thanks to our sponsors, CassianRx and IPC, for supporting independent pharmacy, innovation, and the future of patient-centered care.

You already know GLP-1 medications like Ozempic, Wegovy, and Zepbound can be game changers for weight loss. But could they also be quietly protecting your brain from addiction?In this episode, Lisa Oldson, MD breaks down a landmark new study published in Frontiers in Psychiatry, the largest real-world analysis of its kind, which found that people taking GLP-1 medications were dramatically less likely to develop alcohol, opioid, nicotine, and cocaine use disorders. The numbers are stunning, and the brain science behind them is even more fascinating.Whether you're on a GLP-1 medication, considering one, or simply trying to understand your own cravings and habits, this episode offers a compassionate, science-backed perspective that might just shift the way you think about willpower, the brain, weight, wine, and behavior change.Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also, we'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.The Smart Weight Loss Coaching Podcast is for informational purposes only and does not constitute medical advice. Always consult your physician or a qualified healthcare provider before starting, stopping, or changing any medication.

Do you actually need to exercise on a GLP-1?If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound and wondering whether workouts really matter for weight loss, this episode is for you.In this episode, Registered Dietitian and Certified Personal Trainer Gianna breaks down the science behind fat loss vs muscle loss on GLP-1 medications, and why movement, strength training, and protein intake matter for long-term success.Spoiler alert: losing weight is not automatically the same thing as improving body composition, protecting muscle, or supporting your metabolism.We're covering:Whether exercise is necessary on a GLP-1Why muscle loss can happen during rapid weight lossThe difference between fat loss and lean mass lossWhy strength training matters for metabolism and long-term resultsThe best types of exercise to focus on while taking a GLP-1How much exercise you actually needWhy protein and resistance training work togetherThe biggest exercise myths people believe about GLP-1 medicationsWhether you're brand new to GLP-1s or already losing weight on Ozempic, Wegovy, Mounjaro, or Zepbound, this episode will help you focus on building a healthier, stronger body (not just a smaller one).⭐ LOVE THIS EPISODE?If this episode helped you, it would mean so much if you:Follow the podcastLeave a rating + reviewShare this with a GLP-1 bestie who needs it

Here's a shocking number: One out of eight American adults is taking a GLP-1, like Ozempic or Zepbound, according to a KFF poll. GLP-1s are the biggest pharmaceutical story since antidepressants. But there's still so much we don't know. “We're only at the beginning of what's been called this Ozempic era,” the journalist Julia Belluz told me. “I think we're really just at the beginning of discovering the benefits and the harms of these drugs.” These discoveries begin in the research but are also expanding into how we think about our punishing beauty standards and the blurry lines between illness and wellness. Belluz is a contributing Opinion writer and the author, with Kevin Hall, of “Food Intelligence.” She's one of the best health and science reporters I know and has been reporting on GLP-1s for years. In this conversation, Belluz takes me through what we know — and don't know — about GLP-1s, their unexpected uses, how they are clashing with a culture obsessed with thinness and looksmaxxing, and whether everyone should be on them. Mentioned: “The obesity pay gap is worse than previously thought” by The Economist “The Great Ozempic Experiment” by Julia Belluz Book Recommendations: Behave by Robert M. Sapolsky The Poison Squad by Deborah Blum Ultra-Processed People by Chris van Tulleken Thoughts? Guest suggestions? Email us at ezrakleinshow@nytimes.com. You can find transcripts (posted midday) and more episodes of “The Ezra Klein Show” at nytimes.com/ezra-klein-podcast, and you can find Ezra on Twitter @ezraklein. Book recommendations from all our guests are listed at https://www.nytimes.com/article/ezra-klein-show-book-recs. This episode of “The Ezra Klein Show” was produced by Annie Galvin. Fact-checking by Michelle Harris, with Julie Beer. Our senior engineer is Jeff Geld, with additional mixing by Johnny Simon. Our recording engineer is Aman Sahota. Our executive producer is Claire Gordon. The show's production team also includes Marie Cascione, Rollin Hu, Kristin Lin, Emma Kehlbeck, Jack McCordick, Marina King and Jan Kobal. Original music by Pat McCusker. Audience strategy by Shannon Busta. The director of New York Times Opinion Audio is Annie-Rose Strasser. Transcript editing by Sarah Murphy and Marlaine Glicksman. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

GLP-1 medications like Ozempic and Wegovy are everywhere right now. But what do they actually do? And who are they for?Today we're joined by Dr. Spencer Nadolsky, also known as “The Doc Who Lifts.” He's an obesity and lipid specialist physician, founder of Vineyard and ChefRX, and co-host of the Docs Who Lift podcast.Dr. Nadolsky breaks down the science, myths, and real-life impact of GLP-1s, including:What it feels like to be on GLP-1sExpected weight loss resultsComparison of weight loss drugs: Ozempic vs Wegovy vs ZepboundSide effects What happens when you stop taking themAre they ruining metabolism? Muscle? Bones? Relationships!? Are GLP-1s the solution to obesity?Tune in and find out. Links:IG: https://www.instagram.com/drnadolsky/Vineyard: https://joinvineyard.com/ChefRX: https://orders.chefrx.co/get-startedThe Docs Who Lift Podcast: https://drspencer.com/podcast/(00:00:00) Welcome to the podcast. Meet Dr. Nadolsky.(00:06:03) Simple explanation GLP-1s(00:08:23) Who GLP-1s are for(00:11:26) Ozempic vs Wegovy vs Zepbound(00:12:48) Expected weight loss results(00:15:06) Side effects explained(00:23:42) What it feels like to be on GLP-1s(00:27:16) Why people are so emotional about GLP-1s(00:33:27) Are GLP-1s the solution to obesity?(00:39:18) The #1 thing everyone should do for their health(00:42:35) Where to find Dr. NadolskyWant to leave the TTSL Podcast a voicemail? We love your questions and adore hearing from you. https://www.speakpipe.com/TheThickThighsSaveLivesPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The CVG Nation app, for ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠iPhone⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The CVG Nation app, for Android⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fitness FB Group⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Thick Thighs Save Lives Workout Programs⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Constantly Varied Gear's ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Workout Leggings⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The CVG Nation App, for iPhone: https://apps.apple.com/us/app/cvg-nation/id1544802693The CVG Nation App, for Android: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.cvgnationOur Fitness Facebook Group: https://www.facebook.com/groups/416198445414413Thick Thighs Save Lives Workout Programs: https://www.constantlyvariedgear.com/pages/ttsl-daily-lander-with-ebooksConstantly Varied Gear's Workout Leggings: https://www.constantlyvariedgear.com/